Literature DB >> 10631203

Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions.

J E Heffner1, P J Nietert, C Barbieri.   

Abstract

STUDY
OBJECTIVES: To assess the accuracy of pleural fluid (PF) pH in predicting duration of survival of patients with malignant pleural effusions.
DESIGN: Analysis of patient-level data from nine sources retrieved from a MEDLINE search and correspondence with primary investigators. STUDY SELECTION: Published and unpublished studies that report PF pH values and duration of survival of patients with malignant pleural effusions. DATA COLLECTION AND ANALYSIS: Primary investigators supplied patient-level data (n = 417), which was examined by receiver operating characteristic (ROC) analysis, logistic regression, and survival time modeling to determine the utility of PF pH for predicting survival compared with other clinical factors. The primary investigations were graded for study design. MEASUREMENTS AND
RESULTS: Median survival (n = 417) was 4.0 months: PF pH (p < 0.0039) was an independent predictor of survival duration. A PF pH test threshold < or = 7.28 had the highest accuracy for identifying poor 1-, 2-, and 3-month survivals. The predictive accuracies of PF pH (area under the ROC curve range, 0.571 to 0.662) and a PF pH-high-risk tumor (lung, soft tissues, renal, ovary, gastrointestinal, prostate, and oropharynx) model (odds ratio range, 2.91 to 6.67), however, were modest for predicting 1-, 2-, and 3-month survival. Only 54.4% and 62.7% of patients identified by PF pH < or = 7.28 or the PF pH-high-risk tumor model to die within 3 months were correctly classified. Weaknesses of the primary data were identified.
CONCLUSIONS: PF pH has insufficient predictive accuracy for selecting patients for pleurodesis on the basis of estimated survival.

Entities:  

Mesh:

Year:  2000        PMID: 10631203     DOI: 10.1378/chest.117.1.79

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  31 in total

1.  Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT.

Authors:  Rahul Bhatnagar; Ramon Luengo-Fernandez; Brennan C Kahan; Najib M Rahman; Robert F Miller; Nick A Maskell
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

2.  Mortality among patients with pleural effusion undergoing thoracentesis.

Authors:  Erin M DeBiasi; Margaret A Pisani; Terrence E Murphy; Katy Araujo; Anna Kookoolis; A Christine Argento; Jonathan Puchalski
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

3.  Clinically important factors influencing the diagnostic measurement of pleural fluid pH and glucose.

Authors:  Najib M Rahman; Eleanor K Mishra; Helen E Davies; Robert J O Davies; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

4.  Prolonged pleural catheters in the management of pleural effusions due to breast cancer.

Authors:  Ozkan Demirhan; Cetin Ordu; Alper Toker
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

5.  Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

Authors:  Carolyn M Dresler; Jemi Olak; James E Herndon; William G Richards; Ernest Scalzetti; Stewart B Fleishman; Kemp H Kernstine; Todd Demmy; David M Jablons; Leslie Kohman; Thomas M Daniel; George B Haasler; David J Sugarbaker
Journal:  Chest       Date:  2005-03       Impact factor: 9.410

6.  Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.

Authors:  Da-Wei Wu; Wei-An Chang; Kuan-Ting Liu; Meng-Chi Yen; Po-Lin Kuo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

Review 7.  Current best practice in the evaluation and management of malignant pleural effusions.

Authors:  Steven Walker; Anna C Bibby; Nick A Maskell
Journal:  Ther Adv Respir Dis       Date:  2016-10-24       Impact factor: 4.031

8.  Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters.

Authors:  Susana Herrera Lara; Estrella Fernández-Fabrellas; Gustavo Juan Samper; Josefa Marco Buades; Rafael Andreu Lapiedra; Amparo Pinilla Moreno; María Morales Suárez-Varela
Journal:  Lung       Date:  2017-06-27       Impact factor: 2.584

9.  Management of malignant pleural effusions with indwelling pleural catheters or talc pleurodesis.

Authors:  Nadim Srour; Kayvan Amjadi; Alan Forster; Shawn Aaron
Journal:  Can Respir J       Date:  2013 Mar-Apr       Impact factor: 2.409

10.  Proteomic study of benign and malignant pleural effusion.

Authors:  Hongqing Li; Zhonghao Tang; Huili Zhu; Haiyan Ge; Shilei Cui; Weiping Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-05       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.